Since the end of May of the past stock market year 2024, shares of the biopharmaceutical oncology company have risen by approximately 275% to EUR 0.74. According to the analyst firm Sphene Capital, the price target, which was already set around six months ago, is EUR 4.90, offering a further price potential of 562%.